Childhood schizophrenia: Difference between revisions
Magioladitis (talk | contribs) m cleanup including punct move per WP:REFPUNCT using AWB |
Lena08041993 (talk | contribs) →Treatment: Added summarised information from a Cochrane review. |
||
| Line 55: | Line 55: | ||
== Treatment == |
== Treatment == |
||
Current methods in treating early-onset schizophrenia follow a similar approach to the treatment of adult [[schizophrenia]]. Although modes of treatment in this population is largely understudied, the use of [[antipsychotic]] medication is commonly the first line of treatment in addressing symptoms. Recent literature has failed to determine if typical or atypical antipsychotics are most effective in reducing symptoms and improving outcomes.<ref>{{cite journal|last1=Kennedy|first1=E|last2=Kumar|first2=A|last3=Datta|first3=SS|title=Antipsychotic medication for childhood-onset schizophrenia.|journal=Schizophrenia bulletin|date=September 2007|volume=33|issue=5|pages=1082–3|pmid=17670793|doi=10.1093/schbul/sbm080|pmc=2632357}}</ref> When weighing treatment options, it is necessary to consider the averse effects of various medications used to treat [[schizophrenia]] and the potential implications of these effects on development.<ref>{{cite journal|last1=Cohen|first1=D|last2=Bonnot|first2=O|last3=Bodeau|first3=N|last4=Consoli|first4=A|last5=Laurent|first5=C|title=Adverse effects of second-generation antipsychotics in children and adolescents: a Bayesian meta-analysis.|journal=Journal of Clinical Psychopharmacology|date=June 2012|volume=32|issue=3|pages=309–16|pmid=22544019|doi=10.1097/JCP.0b013e3182549259}}</ref> |
Current methods in treating early-onset schizophrenia follow a similar approach to the treatment of adult [[schizophrenia]]. Although modes of treatment in this population is largely understudied, the use of [[antipsychotic]] medication is commonly the first line of treatment in addressing symptoms. Recent literature has failed to determine if typical or atypical antipsychotics are most effective in reducing symptoms and improving outcomes.<ref>{{cite journal|last1=Kennedy|first1=E|last2=Kumar|first2=A|last3=Datta|first3=SS|title=Antipsychotic medication for childhood-onset schizophrenia.|journal=Schizophrenia bulletin|date=September 2007|volume=33|issue=5|pages=1082–3|pmid=17670793|doi=10.1093/schbul/sbm080|pmc=2632357}}</ref> When weighing treatment options, it is necessary to consider the averse effects of various medications used to treat [[schizophrenia]] and the potential implications of these effects on development.<ref>{{cite journal|last1=Cohen|first1=D|last2=Bonnot|first2=O|last3=Bodeau|first3=N|last4=Consoli|first4=A|last5=Laurent|first5=C|title=Adverse effects of second-generation antipsychotics in children and adolescents: a Bayesian meta-analysis.|journal=Journal of Clinical Psychopharmacology|date=June 2012|volume=32|issue=3|pages=309–16|pmid=22544019|doi=10.1097/JCP.0b013e3182549259}}</ref>In 2013, a [[Systematic review|systematic review]] compared the efficacy of atypical antipsychotics versus typical antipsychotics for adolescents: |
||
{| class="wikitable" |
|||
|+ Atypical compared with typical antipsychotics (only short term)<ref name=Kum2013>{{cite journal|last1=Kumar| first1=A| last2=Datta|first2=S| first3=S| last3=Wright|title=Atypical antipsychotics for psychosis in adolescents|journal=Cochrane Database of Systematic Reviews|date=2013|volume=10|url=http://www.cochrane.org/CD009582/SCHIZ_atypical-antipsychotic-medications-for-adolescents-with-psychosis|pages=CD009582.pub2 |DOI=10.1002/14651858.CD009582.pub2}}</ref> |
|||
|- |
|||
! Summary |
|||
|- |
|||
|There is not any convincing evidence suggesting that [[Atypical antipsychotic|atypical antipsychotic]] medications are superior to the older typical medications for the treatment of adolescents with psychosis. However, atypical antipsychotic medications may be more acceptable because fewer symptomatic adverse effects are seen in the short term. Little evidence is available to support the superiority of one atypical antipsychotic medication over another.<ref name=Kum2013/> |
|||
|- |
|||
| style="padding:0;" | |
|||
{| class="wikitable collapsible collapsed" style="width:100%;" |
|||
|- |
|||
! scope="col" style="text-align: left;"| Outcome |
|||
! scope="col" style="text-align: left;"| Findings in words |
|||
! scope="col" style="text-align: left;"| Findings in numbers |
|||
! scope="col" style="text-align: left;"| Quality of evidence |
|||
|- |
|||
! colspan="4" style="text-align: left;"| Global state |
|||
|- |
|||
| Worse or no improvement|| There is no clear difference between the newer atypical antipsychotic drugs and the typical drugs for this global outcome. These findings are based on data of low quality. |
|||
|| [[Relative risk|RR]] 3.3 (0.41 to 26.81) || [[The Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach|Low]] |
|||
|- |
|||
! colspan="4" style="text-align: left;"| Adverse effects |
|||
|- |
|||
| Anticholinergic adverse effects || Atypical probably reduces the chance of experiencing dry mouth, constipation, and blurred vision but often doses of the older drugs are such that these type of adverse effects are to be expected. Lower doses of control drug could have offset this risk. Data are based on moderate quality evidence. |
|||
|| [[Relative risk|RR]] 0.2 (0.05 to 0.8) || [[The Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach|Moderate]] |
|||
|- |
|||
| Leaving the study because of adverse effects || Use of atypical drugs may increase the chance of leaving early because of adverse effects, but the difference between the treatments is not clear. Data supporting this finding are based on moderate quality evidence. |
|||
|| [[Relative risk|RR]] 3.3 (0.41 to 26.81) || [[The Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach|Moderate]] |
|||
|- |
|||
|} |
|||
|} |
|||
==Prognosis== |
==Prognosis== |
||
Revision as of 15:12, 27 July 2017
| Pediatric schizophrenia | |
|---|---|
| Other names | Childhood schizophrenia, childhood type schizophrenia, childhood-onset schizophrenia, early-onset schizophrenia |
| Specialty | Psychiatry |
Pediatric schizophrenia (also known as childhood schizophrenia, childhood-onset schizophrenia, and early-onset schizophrenia) is a type of mental disorder that is characterized by degeneration of thinking, motor, and emotional processes, with onset before age 18 (early onset) or before age 13 (very early onset).[1][2] The disease presents symptoms such as auditory and visual hallucinations, strange thoughts or feelings, and abnormal behavior, profoundly impacting the child's ability to function and sustain normal interpersonal relationships. It typically presents after the age of seven.[1] About 50% of young children diagnosed with schizophrenia experience severe neuropsychiatric symptoms.[3] Diagnostic criteria are similar to those of adult schizophrenia. Diagnosis is based on behavior observed by caretakers and, in some cases depending on age, self reports.
Schizophrenia has no definite cause; however, certain risk factors such as family history seem to correlate. There is no known cure, but childhood schizophrenia is controllable with the help of behavioral therapies and medications.
Signs and symptoms
Schizophrenia is a psychiatric disorder that is expressed in abnormal mental functions and disturbed behavior.
The signs and symptoms of childhood schizophrenia are nearly the same as adult-onset schizophrenia. Some of the earliest signs that a young child may develop schizophrenia are lags in language and motor development. Some children engage in activities such as flapping the arms or rocking, and may appear anxious, confused, or disruptive on a regular basis. Children may experience symptoms such as hallucinations, but these are often difficult to differentiate from just normal imagination or child play. It is often difficult for children to describe their hallucinations or delusions, making early-onset schizophrenia especially difficult to diagnose in the earliest stages. The cognitive abilities of children with schizophrenia may also often be lacking, with 20% of patients showing borderline or full intellectual disability.[4]
Very early-onset schizophrenia refers to onset before the age of thirteen. The prodromal phase, which precedes psychotic symptoms, is characterized by deterioration in school performance, social withdrawal, disorganized or unusual behavior, a decreased ability to perform daily activities, a deterioration in self-care skills, bizarre hygiene and eating behaviors, changes in affect, a lack of impulse control, hostility and aggression, and lethargy.[4]
Auditory hallucinations are the most common positive symptom in children. A child's auditory hallucinations may include voices that are conversing with each other or voices that are speaking directly to the children themselves. Many children with auditory hallucinations believe that if they do not listen to the voices, the voices will harm them or someone else. Tactile and visual hallucinations seem relatively rare. Delusions are reported in more than half of children with schizophrenia, but they are usually less complex than those of adults.[5]
Diagnosis
The same criteria are used to diagnose children and adults, but diagnosis of children is more challenging.
 | This article needs additional citations for verification. (April 2015) |
Diagnosis is based on reports by parents or caretakers, teachers, school officials, and others close to the child. A professional who believes a child has schizophrenia usually conducts a series of tests to rule out other causes of behavior, and pinpoint a diagnosis. Three different types of exams are performed: physical, laboratory, and psychological. Physical exams usually cover the basic assessments, including but not limited to; height, weight, blood pressure, and checking all vital signs to make sure the child is healthy.[6] Laboratory tests include electroencephalogram EEG screening and brain imaging scans. Blood tests are used to rule out alcohol or drug effects,[6] and thyroid hormone levels are tested to rule out hyper- or hypothyroidism.
| This article needs additional citations for verification. (April 2015) |
A psychologist or psychiatrist talks to a child about their thoughts, feelings, and behavior patterns. They also inquire about the severity of the symptoms, and the effects they have on the child's daily life. They may also discuss thoughts of suicide or self-harm in these one-on-one sessions.[6] Some symptoms that may be looked at are early language delays, early motor development delays and school problems.[6]
Cause
There is no known single cause or causes of schizophrenia, however, it is a heritable disorder.
Genetic
There is "considerable overlap" in the genetics of childhood-onset and adult-onset schizophrenia, but in childhood-onset schizophrenia there is a higher number of "rare allelic variants".[7] An important gene for adolescent-onset schizophrenia is the catechol-O-methyltransferase gene, a gene that regulates dopamine.[8] Children with schizophrenia have an increase in genetic deletions or duplication mutations
| This article needs additional citations for verification. (April 2015) |
and some have a specific mutation called 22q11 deletion syndrome, which accounts for up to 2% of cases.[9][10]
Neuroanatomical
Neuroimaging studies have found differences between medicated schizophrenic brains and neurotypical brains, though research does not know the cause of the difference.[11] In childhood-onset schizophrenia, there appears to be a faster reduction of gray matter.[11]
Epidemiology
Schizophrenia disorders in children are rare.[1] Boys are twice as likely to be diagnosed with childhood schizophrenia.[12] People have been and still are reluctant to diagnose schizophrenia early on, primarily due to the stigma attached to it.[13]
Prevention
Research efforts are focusing on prevention in identifying early signs from relatives with associated disorders similar with schizophrenia and those with prenatal and birth complications. Prevention has been an ongoing challenge because early signs of the disorder are similar to those of other disorders. Also, some of the schizophrenic related symptoms are often found in children without schizophrenia or any other diagnosable disorder.[13]
Treatment
Current methods in treating early-onset schizophrenia follow a similar approach to the treatment of adult schizophrenia. Although modes of treatment in this population is largely understudied, the use of antipsychotic medication is commonly the first line of treatment in addressing symptoms. Recent literature has failed to determine if typical or atypical antipsychotics are most effective in reducing symptoms and improving outcomes.[14] When weighing treatment options, it is necessary to consider the averse effects of various medications used to treat schizophrenia and the potential implications of these effects on development.[15]In 2013, a systematic review compared the efficacy of atypical antipsychotics versus typical antipsychotics for adolescents:
| Summary | ||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| There is not any convincing evidence suggesting that atypical antipsychotic medications are superior to the older typical medications for the treatment of adolescents with psychosis. However, atypical antipsychotic medications may be more acceptable because fewer symptomatic adverse effects are seen in the short term. Little evidence is available to support the superiority of one atypical antipsychotic medication over another.[16] | ||||||||||||||||||||||||
| ||||||||||||||||||||||||
Prognosis
An early or very-early diagnosis of schizophrenia leads to a worse prognosis than other psychotic disorders.[2] The primary area that children with schizophrenia must adapt to is their social surroundings. It has been found, however, that early-onset schizophrenia carried a more severe prognosis than later-onset schizophrenia. Regardless of treatment, children diagnosed with schizophrenia at an early age suffer diminished social skills, such as educational and vocational abilities.
| This article needs additional citations for verification. (April 2015) |
The grey matter in the cerebral cortex of the brain shrinks over time in people with schizophrenia; the question of whether antipsychotic medication exacerbates or causes this has been controversial. A 2015 meta-analysis found that there is a positive correlation between the cumulative amount of first generation antipsychotics taken by people with schizophrenia and the amount of grey matter loss, and a negative correlation with the cumulative amount of second-generation antipsychotics taken.[17][18]
History
Until the late nineteenth century, children were often diagnosed as suffering from psychosis like schizophrenia, but instead were said to suffer from "pubescent" or "developmental" insanity. Through the 1950s, childhood psychosis began to become more and more common, and psychiatrists began to take a deeper look into the issue.[19]
By the 1960s, "childhood schizophrenia" became known as a "heterogeneous mixture" of different disorders, such as autism, symbiotic psychosis, and dementia infantilis. Childhood schizophrenia was not directly added to the DSM until 1968, when it was added to the DSM-II,[20] which set forth diagnostic criteria similar to that of adult schizophrenia.[19] “Schizophrenia, childhood type” was a DSM-II diagnosis with diagnostic code 295.8*.[20] It's equivalent to “schizophrenic reaction, childhood type” (000-x28) in DSM-I (1952).[20]
The diagnosis of schizophrenia was[when?] often given to children who by today’s standards would be diagnosed as having of autism or pervasive developmental disorder. This may be because the onset of schizophrenia is gradual, with symptoms relating developmental difficulties or abnormalities appearing before psychotic symptoms.
References
- ^ a b c Baribeau DA, Anagnostou E (2013). "A comparison of neuroimaging findings in childhood onset schizophrenia and autism spectrum disorder: a review of the literature". Front Psychiatry. 4: 175. doi:10.3389/fpsyt.2013.00175. PMC 3869044. PMID 24391605.
{{cite journal}}: CS1 maint: unflagged free DOI (link) - ^ a b Clemmensen L, Vernal DL, Steinhausen HC (2012). "A systematic review of the long-term outcome of early onset schizophrenia". BMC Psychiatry. 12: 150. doi:10.1186/1471-244X-12-150. PMC 3521197. PMID 22992395.
{{cite journal}}: CS1 maint: unflagged free DOI (link) - ^ Lambert, LT (April–June 2001). "Identification and management of schizophrenia in childhood". Journal of Child and Adolescent Psychiatric Nursing. 14 (2): 73–80. doi:10.1111/j.1744-6171.2001.tb00295.x. PMID 11883626.
- ^ a b Masi, G.; Mucci, M.; Pari, C. (2006). "Children with schizophrenia: Clinical picture and pharmacological treatment". CNS Drugs. 20 (10): 841–66. doi:10.2165/00023210-200620100-00005. PMID 16999454.
- ^ Spencer, EK; Campbell, M (1994). "Children with schizophrenia: diagnosis, phenomenology, and pharmacotherapy" (PDF). Schizophrenia bulletin. 20 (4): 713–25. doi:10.1093/schbul/20.4.713. PMID 7701278.
- ^ a b c d "Childhood schizophrenia: Tests and diagnosis". Mayo Clinic. 17 December 2010.
- ^ Asarnow RF, Forsyth JK (2013). "Genetics of childhood-onset schizophrenia". Child Adolesc Psychiatr Clin N Am. 22 (4): 675–87. doi:10.1016/j.chc.2013.06.004. PMC 4364758. PMID 24012080.
- ^ Godar SC, Bortolato M (2014). "Gene-sex interactions in schizophrenia: focus on dopamine neurotransmission". Front Behav Neurosci. 8: 71. doi:10.3389/fnbeh.2014.00071. PMC 3944784. PMID 24639636.
{{cite journal}}: CS1 maint: unflagged free DOI (link) - ^ Squarcione C, Torti MC, Di Fabio F, Biondi M (2013). "22q11 deletion syndrome: a review of the neuropsychiatric features and their neurobiological basis". Neuropsychiatr Dis Treat. 9: 1873–84. doi:10.2147/NDT.S52188. PMC 3862513. PMID 24353423.
{{cite journal}}: CS1 maint: unflagged free DOI (link) - ^ Giusti-Rodríguez P, Sullivan PF (2013). "The genomics of schizophrenia: update and implications". J. Clin. Invest. 123 (11): 4557–63. doi:10.1172/JCI66031. PMC 3809776. PMID 24177465.
- ^ a b Brent BK, Thermenos HW, Keshavan MS, Seidman LJ (2013). "Gray matter alterations in schizophrenia high-risk youth and early-onset schizophrenia: a review of structural MRI findings". Child Adolesc Psychiatr Clin N Am. 22 (4): 689–714. doi:10.1016/j.chc.2013.06.003. PMC 3767930. PMID 24012081.
- ^ Gonthier, Misty; Lyon, Mark A. (22 July 2004). "Childhood-Onset Schizophrenia: An Overview". Psychology in the Schools. 41 (7): 803–811. doi:10.1002/pits.20013.
- ^ a b Wicks-Nelson, Allen C.; Israel (2009). "Pervasive developmental disorders and schizophrenia". In Jewell, L. (ed.). Abnormal child and adolescent psychology. Upper Saddle River, NJ: Prentice Hall Higher Education. pp. 327–359. ISBN 9780132359788.
- ^ Kennedy, E; Kumar, A; Datta, SS (September 2007). "Antipsychotic medication for childhood-onset schizophrenia". Schizophrenia bulletin. 33 (5): 1082–3. doi:10.1093/schbul/sbm080. PMC 2632357. PMID 17670793.
- ^ Cohen, D; Bonnot, O; Bodeau, N; Consoli, A; Laurent, C (June 2012). "Adverse effects of second-generation antipsychotics in children and adolescents: a Bayesian meta-analysis". Journal of Clinical Psychopharmacology. 32 (3): 309–16. doi:10.1097/JCP.0b013e3182549259. PMID 22544019.
- ^ a b Kumar, A; Datta, S; Wright, S (2013). "Atypical antipsychotics for psychosis in adolescents". Cochrane Database of Systematic Reviews. 10: CD009582.pub2. doi:10.1002/14651858.CD009582.pub2.
- ^ Vita, A; De Peri, L; Deste, G; Barlati, S; Sacchetti, E (15 September 2015). "The Effect of Antipsychotic Treatment on Cortical Gray Matter Changes in Schizophrenia: Does the Class Matter? A Meta-analysis and Meta-regression of Longitudinal Magnetic Resonance Imaging Studies". Biological psychiatry. 78 (6): 403–12. doi:10.1016/j.biopsych.2015.02.008. PMID 25802081.
- ^ Navari, S; Dazzan, P (November 2009). "Do antipsychotic drugs affect brain structure? A systematic and critical review of MRI findings". Psychological medicine. 39 (11): 1763–77. doi:10.1017/S0033291709005315. PMID 19338710.
- ^ a b Remschmidt H, Schulz 3, Martin M, Warnke A, Trott G (1994). "Childhood Onset Schizophrenia: History of the Concept and Recent Studies" (PDF). Schizophrenia Bulletin. 20 (4): 727–745. doi:10.1093/schbul/20.4.727. PMID 7701279.
{{cite journal}}: CS1 maint: multiple names: authors list (link) CS1 maint: numeric names: authors list (link) - ^ a b c American Psychiatric Association (1968). Diagnostic and Statistical Manual of Mental Disorders, 2nd Edition. Washington, D. C. p. 35.
{{cite book}}: CS1 maint: location missing publisher (link)
Further reading
- Tiffin PA, Welsh P (2013). "Practitioner review: schizophrenia spectrum disorders and the at-risk mental state for psychosis in children and adolescents--evidence-based management approaches". J Child Psychol Psychiatry. 54 (11): 1155–75. doi:10.1111/jcpp.12136. PMID 24102356.